$LGND News

B of A Securities Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $388

Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332

Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator

Ligand Pharmaceuticals: The Bull Case Is A Biotech ARM, The Bear Case Is Just Another Royalty Trust

Ligand Plans $550M Convertible Notes Offering, To Use Notes Sale for Share Buybacks and Corporate Needs

Major Decision: Stephen L Sabba Exercises Options, Realizing $422K At Ligand Pharmaceuticals

Strategic Sale: Jason Haas Decides To Exercise Options Worth $809K At Ligand Pharmaceuticals

Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss

Ligand Reports First Quarter 2026 Financial Results

Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est

Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate

Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement

Ligand to Participate in May Investor Conferences

HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $289

LGND: XOMA Buy Adds 100+ Assets

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252

Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook